Fosamprenavir Calcium Articles

DTC effectiveness doubted as drugmakers are accused of exploiting loopholes

8 September 2008

Stock Commentary - New York week to June 9, 2008

16 June 2008

Vertex sells HIV drug royalty rights to GSK

9 June 2008

GSK's Lexiva OK to use with 100mg ritonavir

22 October 2007

Encouraging data for GSK's Lexiva

6 August 2007

Stock Commentary - New York week to Aug 28, 2006

4 September 2006

Robust long-term safety data for GSK/Vertex' Lexiva

1 August 2005

Vertex losses halved, sales grow 69.6%

1 November 2004

Pharma told: freeze US HIV/AIDS and hep C Rx prices, cut those of Norvir and Fuzeon

25 October 2004

GSK/Vertex' Telzir gets EU clearance

26 July 2004

GSK/Vertex' Lexiva effective in suppressing HIV over two years in therapy-naive patients

19 July 2004

GSK/Vertex' Telzir nears EU approval

5 April 2004

Vertex/GSK

2 February 2004

2003 new product launches reveal increasing role of biotech sector

19 January 2004

New Chemical Entities in 2003

19 January 2004

FDA OKs GSK/Vertex' Lexiva for HIV therapy

27 October 2003

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end